Today, we discuss Trump’s lofty new health plan, see the FDA delay two drug reviews under the new voucher program, and more.

Some major drugmakers are hesitating to participate in the Trump administration's speedier review program for new medicines ...

After getting demolished by the flu last week, I am thrilled to be back in the saddle. Stay healthy, everyone! President ...

This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to ...

When the new U.S. dietary guidelines came out last week, food economist William Masters emailed a few colleagues with a fun ...

The actual “how” of lifestyle medicine — meeting patients where they are, outside of the exam room — is crowded out of the ...

Among Americans, trust in science increased slightly between 2024 and 2025, according to a new Pew Research poll.

WASHINGTON — President Trump on Thursday released a hodgepodge of health care policies that would create new price-control ...

You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and policy of health and ...

STAT's Alex Hogan breaks down #JPM26 on STATus Report: the mood, the big interviews — and all the AI billboards.

The former CEO of Emergent BioSolutions was accused of insider trading by the New York attorney general in connection with a ...

The Novo Nordisk Foundation announced it was giving an additional $850 million to an institute to help commercialize biomedical research in Europe.